Chandraditya Chakraborty, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 8 | 2018 | 2016 | 1.140 |
Why?
|
| Cervix Uteri | 2 | 2017 | 583 | 0.860 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 8506 | 0.570 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2018 | 305 | 0.540 |
Why?
|
| Genes, p16 | 1 | 2016 | 159 | 0.520 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2016 | 101 | 0.520 |
Why?
|
| Multiple Myeloma | 5 | 2024 | 5129 | 0.470 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 611 | 0.470 |
Why?
|
| beta Catenin | 1 | 2017 | 1043 | 0.410 |
Why?
|
| DNA Methylation | 5 | 2018 | 4373 | 0.340 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 3609 | 0.330 |
Why?
|
| Human papillomavirus 16 | 4 | 2015 | 266 | 0.320 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 2872 | 0.300 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 3480 | 0.280 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 1888 | 0.280 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 2800 | 0.260 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2015 | 384 | 0.260 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 2825 | 0.250 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 5248 | 0.220 |
Why?
|
| Promoter Regions, Genetic | 5 | 2018 | 5779 | 0.210 |
Why?
|
| HeLa Cells | 2 | 2018 | 3096 | 0.190 |
Why?
|
| 14-3-3 Proteins | 1 | 2020 | 221 | 0.160 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2019 | 198 | 0.160 |
Why?
|
| Ecosystem | 1 | 2022 | 487 | 0.150 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2022 | 633 | 0.150 |
Why?
|
| Papillomavirus Infections | 3 | 2015 | 1612 | 0.150 |
Why?
|
| Evolution, Molecular | 2 | 2023 | 1885 | 0.130 |
Why?
|
| Genomics | 3 | 2023 | 5789 | 0.120 |
Why?
|
| Prognosis | 2 | 2021 | 29558 | 0.120 |
Why?
|
| Oligopeptides | 1 | 2020 | 1185 | 0.120 |
Why?
|
| Ubiquitin | 1 | 2019 | 837 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 6313 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2024 | 1973 | 0.120 |
Why?
|
| Genomic Instability | 3 | 2024 | 704 | 0.120 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2015 | 342 | 0.110 |
Why?
|
| Alphapapillomavirus | 1 | 2016 | 219 | 0.110 |
Why?
|
| Cell Transformation, Viral | 1 | 2015 | 526 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 11152 | 0.110 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2015 | 438 | 0.110 |
Why?
|
| Epithelium | 1 | 2017 | 1605 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2022 | 2909 | 0.100 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 2012 | 0.100 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2011 | 111 | 0.100 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 16886 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 13591 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 1648 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3840 | 0.080 |
Why?
|
| Mutation | 3 | 2021 | 29915 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 996 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2024 | 4641 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2015 | 2194 | 0.070 |
Why?
|
| Survival Rate | 2 | 2021 | 12721 | 0.070 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1740 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2016 | 8297 | 0.060 |
Why?
|
| Repressor Proteins | 2 | 2015 | 2980 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2015 | 3754 | 0.060 |
Why?
|
| Humans | 15 | 2024 | 758381 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 6127 | 0.050 |
Why?
|
| Melphalan | 1 | 2024 | 420 | 0.050 |
Why?
|
| Female | 10 | 2021 | 390316 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 178 | 0.050 |
Why?
|
| Deoxyribonucleases | 1 | 2023 | 211 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 4023 | 0.050 |
Why?
|
| India | 2 | 2015 | 2329 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 1404 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2504 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 2626 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2023 | 2930 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 370 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2016 | 442 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 125 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2023 | 2825 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3574 | 0.030 |
Why?
|
| Virus Integration | 1 | 2015 | 302 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 6209 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2024 | 3006 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 584 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2011 | 814 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2015 | 1356 | 0.020 |
Why?
|
| Aged | 3 | 2015 | 168217 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 15773 | 0.020 |
Why?
|
| Disease Progression | 2 | 2015 | 13468 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 1444 | 0.020 |
Why?
|
| Middle Aged | 3 | 2015 | 219560 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2021 | 10417 | 0.020 |
Why?
|
| Mice | 2 | 2023 | 81107 | 0.020 |
Why?
|
| Apoptosis | 1 | 2021 | 9468 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 15594 | 0.010 |
Why?
|
| Animals | 2 | 2023 | 167777 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 20052 | 0.010 |
Why?
|
| Prevalence | 1 | 2015 | 15646 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 9575 | 0.010 |
Why?
|
| Inflammation | 1 | 2015 | 10719 | 0.010 |
Why?
|
| Male | 2 | 2023 | 358742 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17768 | 0.010 |
Why?
|
| Adult | 2 | 2015 | 219916 | 0.010 |
Why?
|